San Diego-based diagnostic testing company Quidel Corp. has received clearance from the U.S. Food and Drug Administration for a new respiratory virus detection test.

The test distinguishes between two similar viruses that cause breathing infections. Quidel chief scientific officer Timothy Stenzel said in a statement that misdiagnosis “can cause ambiguity in assigning a course of treatment.”

The company is focusing on expanding its line of molecular diagnostics, the company said in the statement.

“We are pleased to have received FDA clearance for another molecular diagnostic product,” Douglas Bryant, Quidel president and chief executive officer said in the statement. “We intend to broaden our menu of molecular assays over the next several quarters, and in doing so, will provide our customers with a number of easy to use infectious disease tests.”

— SDBJ Staff Report